Kadmon Holdings Inc (NYSE:KDMN) – Research analysts at Jefferies Group issued their FY2022 earnings per share estimates for shares of Kadmon in a research report issued to clients and investors on Friday. Jefferies Group analyst B. Amin expects that the company will post earnings of ($1.58) per share for the year.
Several other research analysts have also recently weighed in on KDMN. Zacks Investment Research cut Kadmon from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of Kadmon in a research report on Friday, November 17th. Finally, WBB Securities cut Kadmon from a “hold” rating to a “sell” rating and set a $3.00 price objective for the company. in a research report on Monday, October 9th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $8.65.
Kadmon (NYSE:KDMN) last announced its quarterly earnings results on Thursday, November 9th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.04). The business had revenue of $2.28 million during the quarter, compared to the consensus estimate of $5.69 million. Kadmon’s quarterly revenue was down 60.0% on a year-over-year basis. During the same period in the prior year, the business earned ($4.24) EPS.
Several hedge funds have recently bought and sold shares of the company. Susquehanna International Group LLP boosted its position in shares of Kadmon by 3,211.2% during the third quarter. Susquehanna International Group LLP now owns 443,135 shares of the company’s stock worth $1,485,000 after buying an additional 429,752 shares during the period. Crestline Management LP acquired a new position in Kadmon during the third quarter valued at approximately $2,011,000. Old West Investment Management LLC acquired a new position in Kadmon during the third quarter valued at approximately $169,000. Wells Fargo & Company MN boosted its position in Kadmon by 23.2% during the third quarter. Wells Fargo & Company MN now owns 73,956 shares of the company’s stock valued at $247,000 after purchasing an additional 13,923 shares during the last quarter. Finally, Sphera Funds Management LTD. acquired a new position in Kadmon during the third quarter valued at approximately $3,685,000. 51.90% of the stock is owned by institutional investors.
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.